Publikationen, an denen er mitarbeitet Santiago Moreno Guillén (24)

2024

  1. Effectiveness and Safety of Direct-acting Antivirals for Treatment of Adolescents With HCV/HIV Coinfection: Real-world Data From Europe

    Pediatric Infectious Disease Journal, Vol. 43, Núm. 5, pp. E155-E159

2023

  1. Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice

    Journal of Antimicrobial Chemotherapy, Vol. 78, Núm. 6, pp. 1423-1432

  2. Mortality due to non-AIDS-defining cancers among people living with HIV in Spain over 18 years of follow-up

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 20, pp. 18161-18171

  3. Unplanned pregnancies and social and partner support during pregnancy in Spanish women living with HIV

    HIV Medicine, Vol. 24, Núm. 6, pp. 727-737

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Past and future of HIV infection. A document based on expert opinion

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 35, Núm. 2, pp. 131-156

  3. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

  4. Viruses and Mycoplasma pneumoniae are the main etiological agents of community-acquired pneumonia in hospitalized pediatric patients in Spain

    Pediatric pulmonology, Vol. 57, Núm. 1, pp. 253-263

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort

    Clinical Microbiology and Infection, Vol. 27, Núm. 11, pp. 1678-1684

2020

  1. Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study

    The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 10, pp. 3004-3014

  2. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study

    AIDS Research and Therapy, Vol. 17, Núm. 1

  3. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

  4. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

2019

  1. Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors

    PLoS ONE, Vol. 14, Núm. 8

  2. Durability of first-line antiretroviral regimens in the era of integrase inhibitors: A cohort of HIV-positive individuals in Spain, 2014-2015

    Antiviral Therapy, Vol. 24, Núm. 3, pp. 167-175

  3. Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010–2015

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 9, pp. 580-587

  4. Uso de recursos sanitarios y costes asociados al tratamiento antirretroviral de primera línea en españa en la era de los inhibidores de la integrasa

    Pharmaceutical care España, Vol. 21, Núm. 2, pp. 86-109

2018

  1. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  2. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337